z-logo
open-access-imgOpen Access
A randomized trial of 24 versus 48 weeks of peginterferon a-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response
Author(s) -
Khayat Hre,
Yasser Fouad,
Amin He,
Amal Rizk
Publication year - 2012
Publication title -
tropical gastroenterology
Language(s) - English
Resource type - Journals
eISSN - 2320-5792
pISSN - 0250-636X
DOI - 10.7869/tg.2012.27
Subject(s) - ribavirin , medicine , adverse effect , gastroenterology , hepatitis c virus , viral load , randomized controlled trial , genotype , pegylated interferon , hepatitis c , immunology , virus , biology , biochemistry , gene
Little data is available regarding the 24-week therapy with pegylated interferon and ribavirin in Egyptian patients with hepatitis C virus (HCV) genotype 4 infection. We aimed to investigate the efficacy of 24-week versus 48-week peginterferon alpha-2a plus ribavirin therapy in patients with HCV genotype 4 infection with with rapid virological response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here